|
FY2025
12 months to Jul 31, 2025
|
FY2024
12 months to Jul 31, 2024
|
FY2023
12 months to Jul 31, 2023
|
FY2022
12 months to Jul 31, 2022
|
|
|---|---|---|---|---|
| Cash flow from operating activities: | ||||
| Loss | ||||
| Net loss for the year | ||||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Amortization | ||||
| Financial income (expenses), net | ||||
| Depreciation | ||||
| Share-based compensation | ||||
| Share of loss on equity investment | ||||
| Fair value adjustment of warrants | ||||
| Changes in assets and liabilities: | ||||
| Decrease (increase) in amounts receivable | ||||
| Decrease in prepaid expenses | ||||
| (Decrease) increase in accounts payable | ||||
| Increase (decrease) in accrued expenses and other payables | ||||
| Net cash used in operating activities | ||||
| Cash flow from investing activities: | ||||
| Purchase of property and equipment | ||||
| Purchase of short-term investments, net | ||||
| Equity investment in BC Therapeutics | ||||
| Net cash used in investing activities | ||||
| Cash flow from financing activities: | ||||
| Proceeds from exercise of warrants | ||||
| Share and warrant buyback program | ||||
| Proceeds from issuance of shares, net of issuance costs | ||||
| Net cash provided by financing activities | ||||
| Decrease in cash and cash equivalents | ||||
| Increase in cash and cash equivalents | ||||
| Cash and cash equivalents at beginning of year | ||||
| Cash and cash equivalents at end of year | ||||
Loading...
